

Application Note

No. **88**

Life Sciences

Targeted Proteomic Analysis of Central Metabolic Enzymes Using Nano-LC-Triple Quadrupole Mass Spectrometry

Fumio Matsuda^{1,2,3}, Takafumi Iwakura¹, Taisuke Seike¹ and Yutaka Umakoshi⁴



Lire Scienc

■ Abstract

Targeted proteomics is an analytical technique that measures the expression levels of pre-selected target proteins. Nanoliquid chromatography (nano-LC) is used in targeted proteomics because its low flow rates allow greater analytical sensitivity when dealing with samples that contain very small amounts of peptides. Mass spectrometers capable of high-speed operations, such as those with ultra-fast mass spectrometry (UFMS™) technology, are also needed in targeted proteomics to perform the simultaneous analysis of large numbers of targeted proteins. This article describes applying targeted proteomics with nano-LC and ultra-fast mass spectrometry to the analysis of central metabolic enzymes in yeast and cultured human cells.

1. Introduction

A central metabolism is a basic feature shared by a wide range of organisms. For example, baker's yeast (*Saccharomyces cerevisiae*) uses central metabolic pathways to perform a type of fermentation that converts glucose to ethanol and carbon dioxide. The outstanding fermentation performance of *S. cerevisiae* has been a feature of food production since ancient times, such as in baking and the brewing of Japanese sake and wine, and in more recent times for the production of bioethanol. Metabolic engineering of *S. cerevisiae* is also becoming more prevalent, with gene recombination and gene editing techniques used to modify the central metabolic pathways of *S. cerevisiae* to produce a variety of useful compounds.

- 1 Graduate School of Information Science and Technology, Osaka University
- 2 Osaka University Shimadzu Omics Innovation Research Laboratories
- 3 Industrial Biotechnology Initiative Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University
- 4 Solutions COE, Analytical & Measuring Instruments Division, Shimadzu Corporation

Central metabolic pathways also play a role in the ability of the oleaginous yeast *Lipomyces starkeyi* to accumulate large amounts of lipids. In the field of cancer research, associations between a central metabolism and mechanisms of disease are a focus of interest, with cancer cells known to specifically activate metabolic pathways that create lactate from glucose.

The central metabolism functions thanks to some 100 enzymes, which catalyze the reactions on central metabolic pathways. Measuring the expression levels of enzymes on central metabolic pathways offers a shortcut to understanding how the production of useful substances can be enhanced through central metabolism regulation and the associations between disease and central metabolic functions.

Targeted proteomics offers a method for measuring protein expression levels based on mass analysis, which involves obtaining a crude enzyme extract from a biological sample, digesting the enzyme extract with trypsin, and analyzing the resulting mixture of trypsin-digested peptides using the liquid chromatograph-triple quadrupole mass spectrometer.^{1,2)} Before performing this analysis, trypsin-digested peptides that allow quantitative analysis of the target protein must be selected in advance for each targeted protein, after which a list of multiple reaction monitoring (MRM) transitions is used to selectively detect and quantify these peptides. Nano-LC is also used in targeted proteomics because its low flow rates allow greater analytical sensitivity when dealing with samples that contain very small amounts of peptides. Mass spectrometers capable of highspeed operations, such as those with ultra-fast mass spectrometry (UFMS) technology, are also needed in targeted proteomics to perform the simultaneous analysis of large numbers of targeted proteins. This article applies targeted proteomics using nano-LC and ultra-fast mass spectrometry to analyze central metabolic enzymes in yeast and cultured human cells.

1

2. Experiments

2-1. Reagents and Culture Conditions

All solvents used for LC/MS were of LC/MS grade (FUJIFILM Wako Pure Chemical). *S. cerevisiae* was batch cultured in a 200 mL baffled flask filled with 50 mL of SD culture medium (yeast nitrogen base w/o amino acid 6.7 g/L, glucose 20 g/L) at 30 °C and shaken at 120 rpm. Cells were recovered in the logarithmic growth phase. *L. starkeyi* was cultured under the same conditions as *S. cerevisiae* using 50 mL of synthetic culture medium.³⁾ 1.0×10^6 MCF-7 cells were seeded on a 10 cm plate and cultured in DMEM culture medium.

2-2. Preparing Samples for Analysis

The three major steps undertaken to prepare samples for analysis were extracting proteins from biological tissue, reductive alkylation and trypsin digestion of the extracted proteins, and desalination. Proteins were extracted from yeast cells by the following protocol: a 50 mL specimen of culture broth was centrifuged (5000 \times g, 4 °C, 5 min); the supernatant was discarded; and the precipitate was resuspended in an equal amount by weight of cell lysis buffer (50 mM HEPES, 5 % glycerol, 15 mM DTT, 100 mM KCl, 5 mM EDTA, and 1 tablet of cOmplete protease inhibitors cocktail (Roche)). This suspension was then transferred to an Eppendorf tube filled with zirconia beads (enough 0.6 mm beads for 1 PCR tube, 6 mm bead \times 1) and homogenized (3000 r/min, 6 min) in a Beads Crusher µT-12 (TAITEC). The resulting mixture was centrifuged (15000 rpm, 4 °C, 5 min), and the supernatant was transferred to an Eppendorf tube designed for use in proteomics (low protein binding tube) for analysis. The reductive alkylation and trypsin digestion of proteins was performed according to a published method.⁴⁾ Protein extraction from MCF-7 human breast cancer cells and reductive alkylation and trypsin digestion of proteins were performed using the Proteomics Sample Preparation Kit for Cultured Cells (#FMR-001, Funakoshi). Desalination was performed using the commercially available MonoSpin C18 (GL Sciences) or StageTips that were prepared in-house by layering three Empore Octadecyl C18 47 mm Extraction Disks 2215 in a pipette tip designed for use in proteomics.^{5,6)}

2-3. Analytical Conditions for Nano-LC-Triple Quadrupole Mass Spectrometer

This study performed nano-LC with the LC-20ADnano and triple quadrupole mass spectrometry with the LCMS-8040 and LCMS-8060. The analytical conditions are shown in Table 1. Skyline was used for all data analysis. The MRM conditions used to measure the central metabolic enzymes of *S. cerevisiae* were taken from an LC/MS/MS MRM library of metabolic enzymes (yeast). The MRM conditions used to measure the central metabolic enzymes of *L. starkeyi* were prepared in-house (unpublished data). For human MCF-7 cells, text data on 133 target peptides and 398 MRM transitions were taken from published data, input into Skyline, and output as a method for the LC/MS systems. The collision voltage was obtained from the Q1 m/z value using the formula CE = $0.03 \times [Q1 \ m/z] + 4.0$.

Table 1 Nano-LC-Triple Quadrupole Mass Spectrometry System Setup and Analytical Conditions (Example)

LC: LC-20ADnano Eluent A: 0.1 % formic acid + 5 % acetonitrile aq. solution Eluent B: 0.1 % formic acid + 95 % acetonitrile aq. solution Eluent C (for Trap): 0.1 % formic acid aq. Solution Online Degasser: One unit for eluent A and one for eluent B (to prevent mixing) Piping: nanoViper fingertight fitting (Thermo Scientific) Flow Rate: 400 nL/min Gradient: 8. conc. 0 % (0-7 min) - 65 % (45 min) - 100 % (50-65 min) - 75 % (67 min) - 0 % (75-90 min) lipection valve switched to sample introduction side at 5 minutes Trap Flow Rate: 40 µL/min Column Temperature: Not controlled Column: L-column Micro L-C18 0.1 × 150 mm, 3 µm (CERI) Trip: Fortis tip 150-20 (AMR) Interface: None Nebulizer Gas Flow: None Nebulizer Gas Flow: None Nebulizer Gas Flow: None Q1 Resolution: Low Q3 Resolution: Low Q1 Resolution: Low Q1 Gas: 310 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV Detection Method: MRM mode		
Eluent B: 0.1 % formic acid + 95 % acetonitrile aq. solution Cluent C (for Trap): 0.1 % formic acid aq. Solution Online Degasser: One unit for eluent A and one for eluent B (to prevent mixing) Piping: Piping: Piping: A00 nL/min B. conc. 0 % (0-7 min) – 65 % (45 min) – 100 % (50-65 min) – 75 % (67 min) – 0 % (75-90 min) Injection valve switched to sample introduction side at 5 minutes Trap Flow Rate: Column Temperature: Column: Column: Column: L-column Micro L-C18 0.1 × 150 mm, 3 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Fortis tip 150-20 (AMR) Interface: Porting Gas Flow: DL Temperature: LCMS-8040 or LCMS-8060 None DL Temperature: Prying Gas Flow: One O3 Resolution: Low Q3 Resolution: Low Q3 Resolution: Low C1D Gas: 310 kPa (LCMS-8040) 270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV	LC:	LC-20ADnano
Eluent C (for Trap): Online Degasser: One unit for eluent A and one for eluent B (to prevent mixing) Piping: nanoViper fingertight fitting (Thermo Scientific) Flow Rate: 400 nL/min Gradient: B. conc. 0 % (0-7 min) – 65 % (45 min) – 100 % (50-65 min) – 75 % (67 min) – 0 % (75-90 min) Injection valve switched to sample introduction side at 5 minutes Trap Flow Rate: Column Temperature: Column: Column: L-column Micro L-C18 0.1 × 150 mm, 3 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Tip: Fortis tip 150-20 (AMR) Interface: None DL Temperature: LCMS-8040 or LCMS-8060 None DL Temperature: Prying Gas Flow: One O1 Resolution: CID Gas: 310 kPa (LCMS-8040) 270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV	Eluent A:	0.1 % formic acid + 5 % acetonitrile aq. solution
Online Degasser: One unit for eluent A and one for eluent B (to prevent mixing) Piping: nanoViper fingertight fitting (Thermo Scientific) Flow Rate: 400 nL/min B. conc. 0 % (0-7 min) – 65 % (45 min) – 100 % (50-65 min) – 75 % (67 min) – 0 % (75-90 min) Injection valve switched to sample introduction side at 5 minutes Trap Flow Rate: Column Temperature: Not controlled L-column Micro L-C18 0.1 × 150 mm, 3 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Tip: Fortis tip 150-20 (AMR) Interface: None NEbulizer Gas Flow: None DL Temperature: 150 °C Heat Block Temperature: 200 °C Drying Gas Flow: None Q1 Resolution: Q3 Resolution: Low Q3 Resolution: Low Q3 Resolution: Low C1D Gas: 310 kPa (LCMS-8040) 270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV	Eluent B:	0.1 % formic acid + 95 % acetonitrile aq. solution
Piping: prevent mixing) nanoViper fingertight fitting (Thermo Scientific) Flow Rate: 400 nL/min B. conc. 0 % (0-7 min) – 65 % (45 min) – 100 % (50-65 min) – 75 % (67 min) – 0 % (75-90 min) Injection valve switched to sample introduction side at 5 minutes Trap Flow Rate: 40 μL/min Column Temperature: Not controlled Column: L-column Micro L-C18 0.1 × 150 mm, 3 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Tip: Fortis tip 150-20 (AMR) nano-spray interface (AMR) MS: LCMS-8040 or LCMS-8060 Nebulizer Gas Flow: None DL Temperature: 150 °C Heat Block Temperature: 200 °C Drying Gas Flow: None Q1 Resolution: Low Q3 Resolution: Low Q3 Resolution: Low C1D Gas: 310 kPa (LCMS-8040) 270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV	Eluent C (for Trap):	0.1 % formic acid aq. Solution
Flow Rate: Gradient: B. conc. 0 % (0-7 min) – 65 % (45 min) – 100 % (50-65 min) – 75 % (67 min) – 0 % (75-90 min) Injection valve switched to sample introduction side at 5 minutes Trap Flow Rate: Column Temperature: Column: Column: Column: Column: L-column Micro L-C18 0.1 × 150 mm, 3 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Tip: Fortis tip 150-20 (AMR) Interface: Nebulizer Gas Flow: DL Temperature: LCMS-8040 or LCMS-8060 None DL Temperature: Low Column: Column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Tip: Fortis tip 150-20 (AMR) None Nebulizer Gas Flow: None DL Temperature: LCMS-8040 or LCMS-8060 None Column: Column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Trap Column: Low Column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI)	Online Degasser:	
Gradient: B. conc. 0 % (0-7 min) – 65 % (45 min) – 100 % (50-65 min) – 75 % (67 min) – 0 % (75-90 min) Injection valve switched to sample introduction side at 5 minutes Trap Flow Rate: Column Temperature: Column: Column: Column: Column: Column: Column: Column: Column: L-column Micro L-C18 0.1 × 150 mm, 3 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Tip: Fortis tip 150-20 (AMR) MS: COMS-8040 or LCMS-8060 None Nebulizer Gas Flow: None DL Temperature: Leat Block Temperature: Prying Gas Flow: None Q1 Resolution: CID Gas: CID CID Gas: CID	Piping:	nanoViper fingertight fitting (Thermo Scientific)
Column Temperature: Column: Not controlled L-column Micro L-C18 0.1 × 150 mm, 3 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Tip: Interface: Fortis tip 150-20 (AMR) nano-spray interface (AMR) MS: LCMS-8040 or LCMS-8060 Nebulizer Gas Flow: DL Temperature: 150 °C Heat Block Temperature: 200 °C Drying Gas Flow: None Q1 Resolution: Q3 Resolution: Low Q3 Resolution: Low CID Gas: 310 kPa (LCMS-8040) 270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV		B. conc. 0 % (0-7 min) – 65 % (45 min) – 100 % (50-65 min) – 75 % (67 min) – 0 % (75-90 min) Injection valve switched to sample introduction
Column: L-column Micro L-C18 0.1 × 150 mm, 3 μm (CERI) Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Tip: Fortis tip 150-20 (AMR) Interface: nano-spray interface (AMR) MS: LCMS-8040 or LCMS-8060 None DL Temperature: 150 °C Heat Block Temperature: 200 °C Drying Gas Flow: None Q1 Resolution: Low Q3 Resolution: Low CID Gas: 310 kPa (LCMS-8040) 270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV		40 μL/min
Trap Column: L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI) Tip: Fortis tip 150-20 (AMR) Interface: nano-spray interface (AMR) MS: LCMS-8040 or LCMS-8060 None DL Temperature: Heat Block Temperature: Drying Gas Flow: None Q1 Resolution: Low Q3 Resolution: Low Q3 Resolution: Low CID Gas: 310 kPa (LCMS-8040) 270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV		
Tip: Fortis tip 150-20 (AMR) nano-spray interface: nano-spray interface (AMR) MS: LCMS-8040 or LCMS-8060 Nebulizer Gas Flow: None DL Temperature: 150 °C Heat Block Temperature: 200 °C Drying Gas Flow: None Q1 Resolution: Low Q3 Resolution: Low CID Gas: 310 kPa (LCMS-8040) 270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV	Coramin	, , , ,
Interface: nano-spray interface (AMR) MS: LCMS-8040 or LCMS-8060 Nebulizer Gas Flow: None DL Temperature: 150 °C Heat Block Temperature: 200 °C Drying Gas Flow: None Q1 Resolution: Low Q3 Resolution: Low CID Gas: 310 kPa (LCMS-8040) 270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV	Trap Column:	L-column Micro L-C18 0.3 × 5 mm, 5 μm (CERI)
Nebulizer Gas Flow: None DL Temperature: 150 °C Heat Block Temperature: 200 °C Drying Gas Flow: None Q1 Resolution: Low Q3 Resolution: Low CID Gas: 310 kPa (LCMS-8040) 270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV		
DL Temperature: 150 °C Heat Block Temperature: 200 °C Drying Gas Flow: None Q1 Resolution: Low Q3 Resolution: Low CID Gas: 310 kPa (LCMS-8040) 270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV	MS:	LCMS-8040 or LCMS-8060
Heat Block Temperature: 200 °C Drying Gas Flow: None Q1 Resolution: Low Q3 Resolution: Low CID Gas: 310 kPa (LCMS-8040) 270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV	Nebulizer Gas Flow:	None
Drying Gas Flow: None Q1 Resolution: Low Q3 Resolution: Low CID Gas: 310 kPa (LCMS-8040) 270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV		
Q1 Resolution: Low Q3 Resolution: Low CID Gas: 310 kPa (LCMS-8040) 270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV		
Q3 Resolution: Low CID Gas: 310 kPa (LCMS-8040) 270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV		
CID Gas: 310 kPa (LCMS-8040) 270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV		
270 kPa (LCMS-8060) Interface Voltage: 1.4 to 1.7 kV	•	
Interface Voltage: 1.4 to 1.7 kV	CID Ggs:	
	Interface Voltage	,




Fig. 1 Confirming the Stability of Nano-LC Retention Times

3. Results

3-1. Confirming the Stability of Nano-LC Retention Times

Retention time stability on the nano-liquid chromatograph was tested using the MRMplus Retention Time Marker (FMR-002, Funakoshi) as a test proteomic peptide sample. The sample contained a mixture of 12 peptides. (There are published SRM transitions that allow for the detection of each peptide.) When analysis was performed continuously over a period of 1 month, ion source cleaning and FMR-002 analysis were performed once per week (Fig. 1). This weekly analysis of FMR-002 showed that the shift in retention times was within 0.2 minutes and with very little variation in detection sensitivity, confirming that the nano-LC retention times and ion source were stable enough for quantitative analysis (Fig. 1).

3-2. Confirming High-Speed Performance of Triple Quadrupole Mass Spectrometer

Because triple quadrupole mass spectrometers are now capable of operating at increasingly high speeds, the LCMS-8060 needs as little as 0.8 seconds to acquire a single MRM channel of data (dwell time). Paired with a required pause time of 1.0 msec, the LCMS-8060 is capable of acquiring data on 500-555 channels/sec in parallel. One concern with this improvement is that shorter dwell times will lead to mass chromatograms with a lower S/N ratio, which has a negative effect on quantitative accuracy. This concern was tested by acquiring data on a single sample using an MRM method with different dwell times and then comparing the quantitative results. Trypsin-digested proteins were prepared from S. cerevisiae strain S288C cultured in a fully labeled (13C) glucose medium and a ZWF1 gene knockout strain (zwf1 Δ) cultured with non-labeled glucose. Samples for analysis were then prepared by mixing the two tryptic digests at a ratio of 1:1. An MRM method for analyzing central metabolic enzymes was used to measure the relative amounts of non-labeled and ¹³C-labeled ($[zwf1\Delta]/[S288C]$). A data acquisition cycle time of 1200 msec/cycle was used for all dwell times. Examining the results obtained from the LCMS-8040 showed no major variation in relative amounts when the dwell time was reduced from 10 to 3 msec (Fig. 2a). Even when the dwell time was reduced from 10 to 1 msec, the variation in relative amounts remained low and within a factor of 2 (Fig. 2b).10)




Fig. 2 Effect of Dwell Time on Relative Amounts of Peptides
This shows the amounts measured on the system relative to the reference
sample. [0]

The dotted lines show variations by factors of 0.5 and 2.

Performing the same comparison on the LCMS-8060 using an MRM method for analyzing central metabolic enzymes in the oleaginous yeast *L. starkeyi* also showed that the variation in relative amounts remained smaller than a factor of 2 both when the dwell time was reduced from 10 to 3 msec and from 10 to 1 msec (Fig. 2c, and d) (unpublished data). These results confirmed that data can be acquired at high speed on both the LCMS-8040 and LCMS-8060 while maintaining the accuracy of quantitative data.

3-3. Checking MRM Assay Method Transfer

MRM assay development is becoming more expansive and trending towards the ability to measure all proteins across the entire genome of key species, such as humans and mice. Once an MRM assay method is created, it can be transferred between the mass spectrometry systems of different manufacturers. For example, Drabovich et al.9) built an MRM assay that targets 78 human central metabolic enzymes and in the same report published text data on 133 target peptides and 398 transitions for a Thermo Scientific triple quadrupole mass spectrometer. We input this text data into Skyline and then output the data as an MRM assay method for Shimadzu's LC/MS systems. The collision voltage was calculated from the Q1 m/z. (See section 2-3.) Multiple peptides were detected when the MRM assay reprocessed for the LCMS-8040 was used for quantitative proteomic analysis of cultured human MCF-7 cells (breast cancer cells). A linear relationship was also observed between the measured retention time of each peptide and the retention times noted in the literature, showing that the retention times could also be transferred between systems (Fig. 3, unpublished data).




Fig. 3 Checking MRM Assay Method Transfer
The transferred version of the published MRM assay method was used to
perform targeted proteomic analysis of central metabolic enzymes in MCF-7
breast cancer cells: (a) a chromatogram showing detection of GDLGIEIPAEK
assay peptide derived from PKM, and (b) a comparison of published retention
times for assay peptides and measured retention times after method transfer.

3-4. Targeted Proteomic Analysis of Central Metabolic Enzymes in Single-Gene Knockout Mutant Strain of *S. cerevisiae*

S. cerevisiae has an innately powerful ability to produce ethanol. In S. cerevisiae, pyruvate decarboxylase (Pdc1) is a key enzyme on the pathway that generates ethanol (ETOH) from pyruvate (PYR), a product of the glycolytic system. When the gene that codes for Pdc1 is knocked out in an attempt to switch to the biosynthesis of another compound from PYR, the switch does not occur as expected, and levels of ethanol conversion only fall slightly. In a previous study, quantitative proteomic analysis of the *PDC1* gene knockout strain $pdc1\Delta$ and the wild type strain BY4741 was performed and the expression profile of central metabolic enzymes compared.¹¹⁾ The results showed a Pdc1 protein expression level of zero in the pdc1∆ strain (Fig. 4a). However, Pdc5, which exhibits the same function as Pdc1 and is barely expressed under normal circumstances, was expressed at substantially higher levels, and it acted as a backup for Pdc1. We also observed a simultaneous increase in the expression of Hxk1 and Tdh1, enzymes that function at the entrance and at an intermediate point in the glycolytic system, respectively. This shows that other parts of the glycolytic system are also affected by the PDC1 gene.

The GCR2 gene is a global regulator of the glycolytic system, and performing the same analysis with a GCR2 gene knockout strain ($gcr2\Delta$) resulted in the decreased expression of many enzymes in the glycolytic system (Fig. 4b). Various other effects were also observed outside of the central metabolism, including decreased expression of enzymes in the amino-acid biosynthesis pathway and increased expression of enzymes in the trehalose pathway. Metabolic engineering aims to improve the efficiency of target compound production by expressing enzymes that catalyze additional reactions and eliminating enzymes that catalyze unwanted reactions. This study suggests that manipulation of a single site can affect all central metabolic pathways. 11

4. Conclusion

This study applied targeted proteomics with nano-LC and ultrafast mass spectrometry to analyze central metabolic enzymes in yeast and cultured human cells. The results confirmed that nano-LC retention times and the mass spectrometer ion source were stable enough for quantitative analysis (Fig. 1) and that ultra-fast mass spectrometry can be used to acquire data at high speeds while maintaining accurate quantitative data (Fig. 2). Furthermore, this study confirmed that MRM assay methods taken from published data can be transferred for use on different equipment (Fig. 3). Analysis of a single-gene knockout strain of S. cerevisiae also showed that manipulation of a single site can affect all central metabolic pathways (Fig. 4). In conclusion, using targeted proteomics with nano-LC and ultrafast mass spectrometry for the simultaneous quantitative analysis of central metabolic enzymes can provide insights into how the central metabolism can be regulated for improved production of useful substances as well as the associations between disease and central metabolic functions.

Acknowledgments

We would like to thank Professor Hiroaki Takaku and Project Assistant Professor Rikako Sato of the Faculty of Applied Life Sciences, Niigata University of Pharmacy and Medical and Life Sciences, for their help with *Lipomyces starkeyi* cultures and also Etsuko Wakisaka, Hiroshi Kitano, and Atsumi Tomita of (at the time of this research) the Graduate School of Information Science and Technology, Osaka University, for their technical assistance with the proteome analysis performed in this study.




Fig. 4 Targeted Proteomic Analysis of Central Metabolic Enzymes in Single-Gene Knockout Mutant Strain of S. cerevisiae¹¹⁾ The heat map shows the expression of each enzyme in (a) the $pdc1\Delta$ strain and (b) the $gcr2\Delta$ strain relative to the wild type strain.

< References >

- Ohtsuki S. New developments in biochemistry due to quantitative targeted proteomics: Versatile protein quantization technology without antibodies. The Journal of The Japanese Biochemical Society, 2012;84:911-919.
- Marx T. Targeted proteomics. Nature Methods, 2013;10:19-22.
- Takaku, H., Ebina, S., Kasuga, K., Sato, R., Ara, S., Kazama, H., Matsuzawa, T., Yaoi, K., Araki, H., Shida, Y., Ogasawara, W., Ishiya, K., Aburatani, S., & Yamazaki, H. (2021). Isolation and characterization of Lipomyces starkeyi mutants with greatly increased lipid productivity following UV irradiation. J Biosci Bioeng, 131(6), 613-
- Uchida Y, Tachikawa M, Obuchi W, et al. A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice. Fluids Barriers CNS, 2013; 10:21.
- Ishihama Y. Development of solid phase extraction mini-columns for proteome analysis. Bunseki Kagaku, 2008;57:1011-1018.
- Rappsilber J, Mann M, Ishihama Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc. 2007;2: 1896-1906.
- MacLean B, Tomazela DM, Shulman N, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics, 2010; 26:966-968.
- Picotti P, Bodenmiller B, Mueller LN, et al. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell, 2009;138:795-806.
- Drabovich AP, Pavlou MP, Dimitromanolakis A, Diamandis EP. Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay. Mol Cell Proteomics, 2012; 11:422-434.
- Matsuda F, Ogura t, Tomita A, et al. Nano-scale liquid chromatography coupled to tandem mass spectrometry using the multiple reaction monitoring mode based quantitative platform for analyzing multiple enzymes associated with central metabolic pathways of Saccharomyces cerevisiae using ultra fast mass spectrometry, J Biosci Bioeng.2015;119:117-120.
- 11) Matsuda, F., Kinoshita, S., Nishino, S., Tomita, A., & Shimizu, H. (2017). Targeted proteome analysis of single-gene deletion strains of Saccharomyces cerevisiae lacking enzymes in the central carbon metabolism. PLoS ONE, 12(2), e0172742.

UFMS is a trademark of Shimadzu Corporation and its affiliates in Japan and other countries.



Shimadzu Corporation

www.shimadzu.com/an/

For Research Use Only, Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these

products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. See http://www.shimadzu.com/about/trademarks/index.html for details.

Third party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not

they are used with trademark symbol "TM" or "®".

The copyrights for the content of this publication belong to Shimadzu Corporation or the author. The contents of this publication may not be


modified, reproduced, distributed, or otherwise without the prior written consent of the respective rights holders.

Shimadzu does not guarantee the accuracy and/or completeness of information contained in this publication.

Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication.

> Please fill out the survey

Related Products Some products may be updated to newer models.



Related Solutions

